pulmonary arterial hypertension (PAH)
Conditions
Interventions
Observation group:Observation study, no intervention involved
Sponsors
Fuwai Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age >= 18 years. 2) Treatment-naïve and newly diagnosed with any form of PAH through RHC at hospitalization at Fuwai Hospital from Jan 1 2018 to Dec 31 2023. 3) Baseline hemodynamics showing mPAP ?25 mmHg, PAWP?15 mmHg and PVR>3 Wood units (240 dyn·s·cm-5); 4) All variables of interest (WHO FC, 6MWD, NT-proBNP, and TAPSE and estimated sPAP in echocardiography) available at baseline. 5) At least one documented follow-up with NT-ProBNP, WHO-FC, TAPSE and sPAP or 6MWD.
Exclusion criteria
Exclusion criteria: 1) Initial diagnosis of PAH before Jan 1, 2018 2) Other types of PH and PH with Eisenmenger syndrome, confirmed or suspected pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified 4-strata risk assessment instrument;Risk changes from baseline to the first follow-up by modified 4-strata risk assessment instrument; | — |
Secondary
| Measure | Time frame |
|---|---|
| Kaplan–Meier curve;Risk classification by modified 4-strata risk assessment instrument; | — |
Countries
China
Contacts
Public ContactZhihong Liu
Fuwai Hospital
Outcome results
None listed